Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Capitalizing on Psychedelics Drug Market, with 13 Wellness Clinics Across Nine States and Growing

  • Delic Holdings Corp. comprises several businesses—Delic Labs, Meet Delic, and Ketamine Wellness Centers and media properties Reality Sandwich and Delic Radio 
  • The psychedelic drugs market is expected to reach US $9,818.68 million by 2029 – primarily driven by an increase in acceptance for use in mental health
  • The company’s goal is to expand its clinic offering to 60-70% of the American population driving no more than 45-minutes to reach a clinic

Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leader in new medicines and treatments for a modern world, is committed to bringing the science-backed benefits of psychedelics to more people and reframing the conversations about them. The company owns and operates an assortment of related businesses, including two media platforms (Reality Sandwich and Delic Radio), a Health Canada-licensed entity focusing on the research and development of psilocybin vaporization technology (Delic Labs), a premier psychedelic wellness event (Meet Delic), and the largest network of ketamine clinics in the country (Ketamine Wellness Centers). Delic is backed by a team of industry and cannabis veterans who, alongside a diverse network, share a mission to provide education, research, high-quality products, and treatment options to the population. 

The company is uniquely positioned to capitalize on the psychedelic drugs market, an expanding sector whose growth is primarily driven by an increased acceptance of psychedelics use for mental health. According to Data Bridge Market Research, the psychedelic drugs market was valued at US $2,834.72 million in 2021. The market is expected to grow at a CAGR of 16.8%, resulting in a value of US $9,818.68 million by 2029 (

Delic Holdings company has received a Health Canada 56 Health Exemption, which allows Delic’s scientists to do research with numerous compounds outside of psychedelic mushrooms, including MDMA (ecstasy), LSD, DMT (Dimitri), mescaline, and 2C-B. Health Canada also authorized Delic Labs to acquire 60 grams of psilocybin mushrooms from Nectar Health Sciences Laboratory Division Inc. The lab has also applied for a Dealer’s License, which would allow it to commercialize its research into psilocybin and associated IP for medical and research purposes.

In a January interview, Delic CEO and co-founder Matt Stang explained that there are 51.5 million Americans who have experienced a mental health condition, and the ongoing pandemic has only exacerbated the crisis. This increase in mental health issues has led to a stronger demand for alternatives to current treatments with lasting outcomes and fewer side effects (

“At Delic, we have built the most profitable model for scaling the best-in-class care directly to patients through the largest network of mental health clinics in the U.S.,” Stang added. “We see a strong outlook for Delic with the rollout of 15 additional clinics and an expansion into communities where access to these life-changing treatments is very limited. Delic is well-positioned for growth and profitability in 2022 and beyond.”

The company currently operates 13 wellness clinics across nine states and intends to expand the clinic offering to multiple other locations. The company’s long-term vision for expansion is to have 60-70% of the American population within a 45-minute drive of a clinic. The company also anticipates FDA approval being a reality in the future for compounds like MDMA and psilocybin. 

Once the psychedelic drugs have received some form of FDA approval, “Delic will be the place you can go – you’ll have a clinic in your backyard that you go to for psychedelic medicine treatment, just like any other type of pharmaceutical,” Stang explained in an interview. He further noted that these clinics would offer psychedelic treatments on an in-person basis. Qualified professionals will sit with the patients, walk them through the process, offer them the efficacy they seek, and help them [as a result] change their minds and lives (

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.


Select A Month

PsychedelicNewsWire Currently Accepts



Bitcoin Cash

Bitcoin Cash

Doge Coin






USD Coin

USD Coin

Contact us: 415.949.5050